183 related articles for article (PubMed ID: 15319799)
1. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.
Citrome LL
Drugs Today (Barc); 2004 May; 40(5):445-64. PubMed ID: 15319799
[TBL] [Abstract][Full Text] [Related]
2. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
[TBL] [Abstract][Full Text] [Related]
3. Scientific standards: critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia.
Cohen D
J Clin Psychopharmacol; 2008 Aug; 28(4):461-2; author reply 462-4. PubMed ID: 18626279
[No Abstract] [Full Text] [Related]
4. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
5. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.
Galling B; Roldán A; Nielsen RE; Nielsen J; Gerhard T; Carbon M; Stubbs B; Vancampfort D; De Hert M; Olfson M; Kahl KG; Martin A; Guo JJ; Lane HY; Sung FC; Liao CH; Arango C; Correll CU
JAMA Psychiatry; 2016 Mar; 73(3):247-59. PubMed ID: 26792761
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotics and diabetes: review of non-prospective data.
Haddad PM
Br J Psychiatry Suppl; 2004 Apr; 47():S80-6. PubMed ID: 15056599
[TBL] [Abstract][Full Text] [Related]
7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
8. Relationship of atypical antipsychotics with development of diabetes mellitus.
Citrome LL; Jaffe AB
Ann Pharmacother; 2003 Dec; 37(12):1849-57. PubMed ID: 14632602
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach.
Bellantuono C; Tentoni L; Donda P
Hum Psychopharmacol; 2004 Dec; 19(8):549-58. PubMed ID: 15378663
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.
Holt RI; Peveler RC
Diabetologia; 2006 Jul; 49(7):1467-76. PubMed ID: 16752165
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.
Rajkumar AP; Horsdal HT; Wimberley T; Cohen D; Mors O; Børglum AD; Gasse C
Am J Psychiatry; 2017 Jul; 174(7):686-694. PubMed ID: 28103712
[TBL] [Abstract][Full Text] [Related]
12. Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design.
Currie O; Williman J; Mangin D; McKinnon-Gee B; Bridgford P
BMJ Open; 2019 Feb; 9(2):e022984. PubMed ID: 30796116
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Gianfrancesco F; Grogg A; Mahmoud R; Wang RH; Meletiche D
Clin Ther; 2003 Apr; 25(4):1150-71. PubMed ID: 12809963
[TBL] [Abstract][Full Text] [Related]
14. [Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview].
Scheepers-Hoeks AM; Wessels-Basten SJ; Scherders MJ; Bravenboer B; Loonen AJ; Kleppe RT; Grouls RJ
Tijdschr Psychiatr; 2008; 50(10):645-54. PubMed ID: 18951343
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.
Mamakou V; Hackinger S; Zengini E; Tsompanaki E; Marouli E; Serafetinidis I; Prins B; Karabela A; Glezou E; Southam L; Rayner NW; Kuchenbaecker K; Lamnissou K; Kontaxakis V; Dedoussis G; Gonidakis F; Thanopoulou A; Tentolouris N; Zeggini E
BMC Psychiatry; 2018 Aug; 18(1):249. PubMed ID: 30071838
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
[TBL] [Abstract][Full Text] [Related]
17. Study focuses in on potential cause of antipsychotic-induced diabetes.
O'Neill MF
Drug News Perspect; 2005 Oct; 18(8):481-2. PubMed ID: 16391716
[TBL] [Abstract][Full Text] [Related]
18. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
Yogaratnam J; Biswas N; Vadivel R; Jacob R
East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study.
Okumura Y; Ito H; Kobayashi M; Mayahara K; Matsumoto Y; Hirakawa J
Schizophr Res; 2010 Jun; 119(1-3):145-52. PubMed ID: 20304611
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
